Interleukin‐4 inhibits proliferation of human leukemic megakaryoblast cell line mhh 225
- 1 January 1994
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 12 (2) , 61-66
- https://doi.org/10.1002/hon.2900120203
Abstract
The effects of six recombinant human cytokines: erythropoietin, GM‐CSF, G‐CSF, interleukin‐3, ‐4 and ‐6 on the proliferation and differentiation of a human multilineage myeloid leukemia cell line MHH 225, established from the bone marrow of an AML(M7) patient in our laboratory determined by changes in antigen expressions using monoclonal antibodies in APAAP technique were examined in liquid suspension culture. The MHH 225 cells have been growing exponentially without cytokines or conditioned media. About 90 per cent of MHH 225 cells are CD33+CD34+CD3–CD7–CD19–CD20–TdT– with 57.6 per cent, 28.3 per cent and 7.8 per cent of them being CD41+, glycophorin A+ and CD15+, respectively. After five days of treatment with erythropoietin, GM‐CSF, G‐CSF or IL‐6 no change was observed in MHH 225 cell antigens expression. IL‐3 (100 U/ml) induced a moderate increase in only CD13 and alpha naphthyl esterase positive cells from 6.5 ± 1.9 per cent and 5.7 ± 2.4 per cent in control cultures to 21.6 ± 3.0 per cent and 19.1 ± 2.8 per cent, respectively. On the other hand, 100 U/ml IL‐4 significantly increased the number of CD13, CD15 and alpha naphthyl esterase positive cells to 48.9 ± 5.0 per cent, 47.2 ± 3.6 per cent and 46.1 ± 3.0 per cent, p < 0.001, respectively. Also, 100 U/ml IL‐4 decreased the number of CD41 positive cells from 57.6 ± 2.8 per cent to only 25.9 ± 3.6 per cent and did not change the number of CD33 or glycophorin A positive cells. The present results showed that out of the six myelopoietic growth factors tested, IL‐4 was the only one to inhibit selectively the proliferation of CD33+CD41+ leukemic megakaryoblast cells suggesting that IL‐4 may have a lineage regulatory effect in favour of a myeloblastic CD33+CD13+CD15+ at the expense of a megakaryoblastic CD33+CD41+ amplification in human leukemia cells and with apparently no effect on leukemic erythroblast cells. The MHH 225 cell line provides a useful tool and freely available model to scientists for studying signal transduction via IL‐4 and for studies of‘lineage switch’.Keywords
This publication has 10 references indexed in Scilit:
- Hematopoietic growth factors and their receptors in acute leukemiaBlood, 1993
- Interleukin 4 potentiates the antiproliferative effect of 1α,25-dihydroxyvitamin D3 on mouse monocytic leukemia cells but antagonizes the antiproliferative effects of interferon α,β and interleukin 6Leukemia Research, 1992
- IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells.The Journal of Immunology, 1991
- Interleukin-4 inhibits the differentiation of mouse myeloid leukemia M1 cells induced by dexamethasone, D-factor/leukemia inhibitory factor and interleukin-6, but not by 1α,25-dihydroxyvitamin D3FEBS Letters, 1991
- Antiproliferative and differentiative effects of recombinant interleukin-4 on a granulocyte colony-stimulating factor-dependent myeloblastic leukemic cell lineBlood, 1991
- Role of Interleukin‐4 in the Negative Regulation of Proliferation of Chronic Myelomonocytic Leukemia CellsaAnnals of the New York Academy of Sciences, 1991
- Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancyBlood, 1991
- Interleukin-4Annals of Hematology, 1990
- Auer Bodies in Acute Myeloid Leukaemia PatientsPathology - Research and Practice, 1990
- Relation between Age and Blast Cell Differentiation in Acute Myeloid Leukaemia PatientsOncology, 1990